We are the experts in the development, optimization, and characterization of manufacturing processes for recombinant proteins, from DNA through to the entire value chain up to drug substance. This also includes complex proteins with demanding requirements for expression, purification, and stabilization. We rely on economically optimized technology platforms. For your active pharmaceutical ingredient, we develop a customized process or provide efficient process transfer.
With our cell line development platform, we can offer you a “best-in-class” solution for both standard IgGs and complex molecular formats. Our Producer Pool Proof of Concept provides an excellent (“zero-risk”) opportunity to benchmark your molecule(s) on the Rentschler Biopharma CLD platform. The close integration of our in-house CLD platform with the USP platform process design eliminates the need for separate development activities and enables a seamless cGMP transfer.
We are specialized in the development of upstream processes and their optimization for the best possible yield and quality. Our offering includes both platform solutions and processes tailored to your needs, including process characterization and validation. We support cell cultures with fed-batch, continuous and perfusion processes.
We enrich your protein and convert it into a highly purified form. Built on decades of expertise in downstream process development and optimization supported by mechanistic modeling, we are able to achieve maximum yield, cost-effectiveness, and the highest product quality for you. Our services range from platform solutions to individually tailored processes, including process characterization and strict measures to ensure virus safety.
We guarantee a seamless and efficient process establishment with our sophisticated technology transfer capabilities. Whether it’s across laboratory, pilot, or scale-up to production sites, our experience and dedication to tailored solutions ensure a smooth and rapid transition for your operations.
Rentschler Biopharma has a very good track record and reputation, especially for early-stage projects.
— President of an Asian start-up
Monoclonal antibodies
Bi- and multispecific antibodies
Fc fusion proteins
Enzymes, growth and coagulation factors
Modified proteins
Non-Fc fusion proteins
Bispecific antibody fragments
Are you interested in learning more? We look forward to hearing from you!